Methods of treating OX40 medicated recall immune responses
US7291331B1 · kind B1 · utility
40Cited by
3References
54Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2003 |
| Grant date | Nov 6, 2007 |
| Priority date | — |
| Expiry date | Sep 11, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.